StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock.
CEL-SCI Trading Up 0.7 %
Shares of CEL-SCI stock opened at $0.30 on Thursday. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $0.68. The stock has a market cap of $23.47 million, a PE ratio of -0.63 and a beta of 0.67. CEL-SCI has a 52-week low of $0.29 and a 52-week high of $2.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.
Institutional Investors Weigh In On CEL-SCI
A number of large investors have recently bought and sold shares of the company. Thoroughbred Financial Services LLC grew its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares in the last quarter. Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares in the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the third quarter worth about $98,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Read More
- Five stocks we like better than CEL-SCI
- Top Biotech Stocks: Exploring Innovation Opportunities
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Stock Market Sectors: What Are They and How Many Are There?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The How And Why of Investing in Oil Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.